Marcelle Ivonne Cedars

Dr. Marcelle Ivonne Cedars


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
JCJacob Paul Christ
Jacob Paul Christ
MCMarcelle Ivonne Cedars
Marcelle Ivonne Cedars
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive-aged women. Much of the confusion surrounding PCOS diagnosis stems from the broad heterogeneity of symptomology experienced by women with PCOS. The diverse features of the syndrome have led to a number of diagnostic criteria over the years. This manuscript describes each of the current composite criteria and individually breaks down each component. The importance of accurate diagnosis for both clinical care and research is emphasized.

1 February 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
MCMarcelle Ivonne Cedars
Marcelle Ivonne Cedars
Context: Evaluation of the infertile female requires an understanding of ovulation and biomarkers of ovarian reserve. Antimüllerian hormone (AMH) correlates with growing follicles in a menstrual cycle. Increasingly, AMH has been used as a “fertility test.” This narrative review describes how to integrate the use of AMH into diagnosis and treatment. Methods: A PubMed search was conducted to find recent literature on measurements and use of serum AMH as a marker of ovarian reserve and in treatment of infertility. Results: Serum AMH estimates ovarian reserve, helps determine dosing in ovarian stimulation, and predicts stimulation response. As such, AMH is a good marker of oocyte quantity but does not reflect oocyte health or chances for pregnancy. Screening of AMH before fertility treatment should be used to estimate expected response and not to withhold treatment. Low AMH levels may suggest a shortened reproductive window. AMH levels must be interpreted in the context of the endogenous endocrine environment where low follicle-stimulating hormone, due to hypogonadotropic hypogonadism or hormonal contraceptive use, may lower AMH without being a true reflection of ovarian reserve. In addition, there is an inverse correlation between body mass index and AMH that does not reflect ovarian response. Conclusion: AMH is a useful marker of ovarian reserve in reproductive-aged women. Increased screening of noninfertile women requires a thorough knowledge of situations that may affect AMH levels. In no situation does AMH reflect oocyte health or chances for conception. Age is still the strongest driver in determining success rates with fertility treatments.

1 September 2018 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
EGEleni A. Greenwood
Eleni A. Greenwood
LPLauri A. Pasch
Lauri A. Pasch
MCMarcelle Ivonne Cedars
Marcelle Ivonne Cedars
RLRichard S. Legro
Richard S. Legro
HHHeather G. Huddleston
Heather G. Huddleston

30 March 2022 in Fertility and Sterility
Verified
Journal Article
Closed access
MCMarcelle Ivonne Cedars
Marcelle Ivonne Cedars

1 October 2018 in Fertility and Sterility
Verified
Journal Article
Closed access
MQMolly M. Quinn
Molly M. Quinn
MCMarcelle Ivonne Cedars
Marcelle Ivonne Cedars

20 July 2022 in Obstetrics & Gynecology
Verified
Journal Article
Open access
EFEve C. Feinberg
Eve C. Feinberg
JKJennifer F. Kawwass
Jennifer F. Kawwass
MCMarcelle Ivonne Cedars
Marcelle Ivonne Cedars
On June 24, 2022, the U.S. Supreme Court ruling in Dobbs v Jackson Women's Health overturned Roe v Wade, and authority to regulate abortion was returned to individual states. It is critically important for all physicians to understand the implications that this ruling may have on reproductive autonomy with regard to abortion care and in vitro fertilization (IVF). Although the intended consequence of abortion bans is to prohibit legal abortion, one unintended consequence may be undue restriction of in vitro fertilization. We summarize the potential of abortion bans, particularly those with personhood clauses, to affect IVF practice. We detail the implications of these bans on embryo cryopreservation, preimplantation genetic testing, single embryo transfer, and access to infertility treatments. In the United States in 2019, nearly 84,000 children were born as a result of IVF (2.2% of all births), and nearly 250,000 IVF cycles were performed. These bans will have a profound effect beyond abortion, and these implications are not widely understood in the medical community.